26.28
price up icon1.82%   0.47
after-market Handel nachbörslich: 26.24 -0.04 -0.15%
loading
Schlusskurs vom Vortag:
$25.81
Offen:
$25.72
24-Stunden-Volumen:
4.99M
Relative Volume:
0.82
Marktkapitalisierung:
$2.96B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-99.15M
KGV:
-28.26
EPS:
-0.93
Netto-Cashflow:
$-74.25M
1W Leistung:
+5.25%
1M Leistung:
-2.85%
6M Leistung:
+8.82%
1J Leistung:
-58.49%
1-Tages-Spanne:
Value
$25.04
$26.55
1-Wochen-Bereich:
Value
$24.78
$26.96
52-Wochen-Spanne:
Value
$18.92
$81.73

Viking Therapeutics Inc Stock (VKTX) Company Profile

Name
Firmenname
Viking Therapeutics Inc
Name
Telefon
858-704-4660
Name
Adresse
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Name
Mitarbeiter
49
Name
Twitter
@viking_vktx
Name
Nächster Verdiensttermin
2025-07-23
Name
Neueste SEC-Einreichungen
Name
VKTX's Discussions on Twitter

Vergleichen Sie VKTX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
VKTX
Viking Therapeutics Inc
26.28 2.90B 0 -99.15M -74.25M -0.93
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
391.64 101.35B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
456.00 58.66B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
562.27 59.43B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ARGX
Argen X Se Adr
737.56 44.01B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
340.70 36.56B 3.81B -644.79M -669.77M -6.24

Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-29 Eingeleitet Cantor Fitzgerald Overweight
2025-04-08 Eingeleitet Goldman Neutral
2025-02-13 Eingeleitet Scotiabank Sector Outperform
2025-02-07 Eingeleitet Citigroup Neutral
2024-12-02 Eingeleitet Piper Sandler Overweight
2024-11-22 Eingeleitet B. Riley Securities Buy
2024-11-04 Bestätigt H.C. Wainwright Buy
2024-09-11 Eingeleitet JP Morgan Overweight
2024-06-27 Eingeleitet Morgan Stanley Overweight
2024-05-16 Hochstufung Raymond James Outperform → Strong Buy
2024-03-26 Bestätigt Oppenheimer Outperform
2024-03-07 Eingeleitet Jefferies Buy
2024-02-28 Bestätigt Oppenheimer Outperform
2023-05-31 Fortgesetzt ROTH MKM Buy
2023-03-28 Bestätigt Maxim Group Buy
2023-03-17 Eingeleitet Stifel Buy
2021-07-29 Fortgesetzt BTIG Research Buy
2021-05-25 Herabstufung Raymond James Strong Buy → Outperform
2020-06-05 Eingeleitet BMO Capital Markets Outperform
2020-05-05 Eingeleitet Chardan Capital Markets Buy
2020-05-01 Eingeleitet BTIG Research Buy
2019-07-16 Eingeleitet Oppenheimer Outperform
2019-06-25 Eingeleitet Stifel Buy
2019-03-29 Hochstufung SVB Leerink Mkt Perform → Outperform
2019-03-14 Bestätigt Maxim Group Buy
2019-02-22 Eingeleitet SVB Leerink Mkt Perform
2018-12-12 Eingeleitet B. Riley FBR Buy
2018-11-19 Hochstufung Raymond James Outperform → Strong Buy
2018-09-18 Bestätigt H.C. Wainwright Buy
2018-09-18 Bestätigt Maxim Group Buy
2018-09-18 Bestätigt Raymond James Outperform
2018-07-20 Eingeleitet SunTrust Buy
2018-06-28 Eingeleitet Raymond James Outperform
2018-06-01 Bestätigt Laidlaw Buy
2018-05-31 Bestätigt Maxim Group Buy
2018-03-26 Fortgesetzt H.C. Wainwright Buy
2017-11-28 Bestätigt Maxim Group Buy
2017-11-21 Eingeleitet ROTH Capital Buy
Alle ansehen

Viking Therapeutics Inc Aktie (VKTX) Neueste Nachrichten

pulisher
Sep 30, 2025

Applying Elliott Wave Theory to Viking Therapeutics Inc.July 2025 Review & AI Enhanced Trade Execution Alerts - newser.com

Sep 30, 2025
pulisher
Sep 30, 2025

Will Viking Therapeutics Inc. stock attract more institutional investors2025 Top Decliners & Technical Buy Zone Confirmations - newser.com

Sep 30, 2025
pulisher
Sep 30, 2025

BTIG Reiterates a Buy Rating on Viking Therapeutics (VKTX) With a $125 PT - Yahoo Finance

Sep 30, 2025
pulisher
Sep 30, 2025

BTIG Reiterates a Buy Rating on Viking Therapeutics (VKTX) - MSN

Sep 30, 2025
pulisher
Sep 30, 2025

Why This Beaten-Down GLP-1 Stock Could Be a Steal - AOL.com

Sep 30, 2025
pulisher
Sep 30, 2025

Why This Beaten-Down GLP-1 Stock Could Be a Steal - The Motley Fool

Sep 30, 2025
pulisher
Sep 30, 2025

What to expect from Viking Therapeutics Inc. in the next 30 daysQuarterly Portfolio Summary & Long-Term Safe Investment Plans - newser.com

Sep 30, 2025
pulisher
Sep 29, 2025

HC Wainwright & Co. Reiterates Viking Therapeutics (VKTX) Buy Recommendation - Nasdaq

Sep 29, 2025
pulisher
Sep 29, 2025

H.C. Wainwright Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $102 - 富途牛牛

Sep 29, 2025
pulisher
Sep 29, 2025

Viking Therapeutics: Promising Position in GLP-1 Market with Strategic Growth Potential - TipRanks

Sep 29, 2025
pulisher
Sep 29, 2025

VKTX: HC Wainwright Reiterates Buy Rating and Maintains Price Ta - GuruFocus

Sep 29, 2025
pulisher
Sep 29, 2025

Viking Therapeutics' (VKTX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

Sep 29, 2025
pulisher
Sep 29, 2025

Is Viking Therapeutics Inc. reversing from oversold territoryWeekly Investment Report & Safe Capital Growth Tips - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Will Viking Therapeutics Inc. stock maintain momentum in 2025Watch List & Verified Momentum Stock Alerts - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Is Viking Therapeutics Inc. stock oversold or undervaluedJuly 2025 Catalysts & Free High Accuracy Swing Entry Alerts - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Short interest data insights for Viking Therapeutics Inc.Trade Entry Summary & Stepwise Trade Execution Plans - newser.com

Sep 29, 2025
pulisher
Sep 28, 2025

Viking Therapeutics: Overdue For Gains (NASDAQ:VKTX) - Seeking Alpha

Sep 28, 2025
pulisher
Sep 28, 2025

What drives Viking Therapeutics Inc 1VT stock priceResistance Breakout Alerts & Small Investment Capital Gains - earlytimes.in

Sep 28, 2025
pulisher
Sep 28, 2025

Is Viking Therapeutics Inc a good long term investmentTechnical Analysis Insights & Low Risk Wealth Plans - Early Times

Sep 28, 2025
pulisher
Sep 27, 2025

Using flow based indicators on Viking Therapeutics Inc.July 2025 Outlook & Weekly Return Optimization Alerts - newser.com

Sep 27, 2025
pulisher
Sep 27, 2025

Analyzing Viking Therapeutics Inc. with risk reward ratio chartsVolume Spike & Weekly Watchlist for Hot Stocks - newser.com

Sep 27, 2025
pulisher
Sep 26, 2025

Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock is a Safer Bet? - MSN

Sep 26, 2025
pulisher
Sep 26, 2025

Pfizer Is Buying Weight Loss Biotech Metsera. Here's Why Viking Therapeutics Shareholders May Be Cheering. - MSN

Sep 26, 2025
pulisher
Sep 26, 2025

Viking Therapeutics: A Huge Reward Or A Total Loss (NASDAQ:VKTX) - Seeking Alpha

Sep 26, 2025
pulisher
Sep 26, 2025

Pfizer Acquires Metsera, Viking Therapeutics’ Prospects Attract Attention - NAI500

Sep 26, 2025
pulisher
Sep 25, 2025

Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors - sharewise.com

Sep 25, 2025
pulisher
Sep 25, 2025

Viking Therapeutics (NASDAQ:VKTX) Shares Down 5.8%Here's Why - MarketBeat

Sep 25, 2025
pulisher
Sep 25, 2025

Can Viking Therapeutics Hold Its Edge as Obesity Rivalry Heats Up? - sharewise.com

Sep 25, 2025
pulisher
Sep 25, 2025

Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet - sharewise.com

Sep 25, 2025
pulisher
Sep 24, 2025

Viking Therapeutics Stock Surges on Promising Obesity Drug Pipeline - AD HOC NEWS

Sep 24, 2025
pulisher
Sep 24, 2025

Viking Therapeutics (NASDAQ:VKTX) Trading 6.6% HigherTime to Buy? - MarketBeat

Sep 24, 2025
pulisher
Sep 24, 2025

Viking Therapeutics (NASDAQ:VKTX) Trading 7.4% HigherWhat's Next? - MarketBeat

Sep 24, 2025
pulisher
Sep 24, 2025

Viking Therapeutics : September 2025 Corporate Presentation - MarketScreener

Sep 24, 2025
pulisher
Sep 24, 2025

Are Safety Concerns Around VK2735 Shaping Investor Perceptions of Viking Therapeutics (VKTX)? - simplywall.st

Sep 24, 2025
pulisher
Sep 24, 2025

Why Viking Therapeutics Stock Crashed Today - aol.com

Sep 24, 2025
pulisher
Sep 24, 2025

U.S. Capital Wealth Advisors LLC Purchases 27,795 Shares of Viking Therapeutics, Inc. $VKTX - MarketBeat

Sep 24, 2025
pulisher
Sep 23, 2025

Viking Therapeutics Shares Dip as Pfizer Chooses Rival Acquisition - AD HOC NEWS

Sep 23, 2025
pulisher
Sep 23, 2025

Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know - sharewise.com

Sep 23, 2025
pulisher
Sep 23, 2025

Pfizer’s $5B Bet on Metsera ($MTSR) vs Viking Therapeutics ($VKTX) - MSN

Sep 23, 2025
pulisher
Sep 23, 2025

Strs Ohio Invests $604,000 in Viking Therapeutics, Inc. $VKTX - MarketBeat

Sep 23, 2025
pulisher
Sep 23, 2025

Viking Therapeutics at Bernstein Forum: Strategic Moves in Obesity Market - Investing.com

Sep 23, 2025
pulisher
Sep 23, 2025

Transcript : Viking Therapeutics, Inc. Presents at Bernstein 2nd Annual Global Healthcare Conference, Sep-23-2025 11 - MarketScreener

Sep 23, 2025
pulisher
Sep 23, 2025

Viking Therapeutics at Bernstein Forum: Strategic Moves in Obesity Market By Investing.com - Investing.com UK

Sep 23, 2025
pulisher
Sep 23, 2025

Viking Therapeutics Stock Gets Boost From Pfizer-Metsera Deal, Says BTIG — Retail Slams Rivals For Buying ‘Inferior Pipelines’ - Stocktwits

Sep 23, 2025
pulisher
Sep 23, 2025

Exchange Traded Concepts LLC Buys 20,296 Shares of Viking Therapeutics, Inc. $VKTX - MarketBeat

Sep 23, 2025
pulisher
Sep 22, 2025

Viking Therapeutics: Oral Study Disappoints, Competitor Gets Bought Out (Rating Downgrade) - Seeking Alpha

Sep 22, 2025
pulisher
Sep 22, 2025

Why Viking Therapeutics Shares Are Climbing High - TipRanks

Sep 22, 2025
pulisher
Sep 22, 2025

BTIG Reiterates Buy Rating for Viking Therapeutics (VKTX) with $125 Target | VKTX Stock News - GuruFocus

Sep 22, 2025
pulisher
Sep 22, 2025

BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125 - 富途牛牛

Sep 22, 2025
pulisher
Sep 22, 2025

Viking Therapeutics (NASDAQ:VKTX) Earns Buy Rating from BTIG Research - MarketBeat

Sep 22, 2025
pulisher
Sep 22, 2025

Viking Therapeutics: Strong Buy Rating Amid Strategic Positioning and Acquisition Potential in the Metabolic Disease Market - TipRanks

Sep 22, 2025

Finanzdaten der Viking Therapeutics Inc-Aktie (VKTX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.66
price down icon 2.36%
$84.81
price up icon 1.10%
$30.67
price up icon 4.57%
$98.62
price up icon 0.53%
$144.01
price up icon 1.67%
biotechnology ONC
$340.70
price up icon 2.36%
Kapitalisierung:     |  Volumen (24h):